Literature DB >> 17567690

Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions.

Erin E Verity1, Dimitra Zotos, Kim Wilson, Catherine Chatfield, Victoria A Lawson, Dominic E Dwyer, Anthony Cunningham, Jennifer Learmont, Wayne Dyer, John Sullivan, Melissa Churchill, Steven L Wesselingh, Dana Gabuzda, Paul R Gorry, Dale A McPhee.   

Abstract

The Sydney Blood Bank Cohort (SBBC) consists of eight blood transfusion recipients infected with nef-attenuated human immunodeficiency virus type 1 (HIV-1) acquired from a single donor. Here, we show that viral phenotypes and antibody responses differ considerably between individual cohort members, despite the single source of infection. Replication of isolated virus varied from barely detectable to similar to that of the wild-type virus, and virus isolated from five SBBC members showed coreceptor usage signatures unique to each individual. Higher viral loads and stronger neutralizing antibody responses were associated with better-replicating viral strains, and detectable viral replication was essential for the development of strong and sustained humoral immune responses. Despite the presence of strong neutralizing antibodies in a number of SBBC members, disease progression was not prevented, and each cohort member studied displayed a unique outcome of infection with nef-attenuated HIV-1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17567690      PMCID: PMC1951448          DOI: 10.1128/JVI.00650-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.

Authors:  John R Mascola; Patricia D'Souza; Peter Gilbert; Beatrice H Hahn; Nancy L Haigwood; Lynn Morris; Christos J Petropoulos; Victoria R Polonis; Marcella Sarzotti; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

2.  Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source.

Authors:  Melissa J Churchill; David I Rhodes; Jennifer C Learmont; John S Sullivan; Steven L Wesselingh; Ian R C Cooke; Nicholas J Deacon; Paul R Gorry
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection.

Authors:  A Brambilla; L Turchetto; A Gatti; C Bovolenta; F Veglia; E Santagostino; A Gringeri; M Clementi; G Poli; P Bagnarelli; E Vicenzi
Journal:  Virology       Date:  1999-07-05       Impact factor: 3.616

4.  Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells.

Authors:  Xugang Qiao; Bing He; April Chiu; Daniel M Knowles; Amy Chadburn; Andrea Cerutti
Journal:  Nat Immunol       Date:  2006-01-22       Impact factor: 25.606

5.  Identification of attenuated variants of HIV-1 circulating recombinant form 01_AE that are associated with slow disease progression due to gross genetic alterations in the nef/long terminal repeat sequences.

Authors:  Makiko Kondo; Takako Shima; Masako Nishizawa; Koji Sudo; Shinya Iwamuro; Takeshi Okabe; Yutaka Takebe; Mitsunobu Imai
Journal:  J Infect Dis       Date:  2005-05-25       Impact factor: 5.226

6.  Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia.

Authors:  Melissa Churchill; Jasminka Sterjovski; Lachlan Gray; Daniel Cowley; Catherine Chatfield; Jennifer Learmont; John S Sullivan; Suzanne M Crowe; John Mills; Bruce J Brew; Steven L Wesselingh; Dale A McPhee; Paul R Gorry
Journal:  J Infect Dis       Date:  2004-11-16       Impact factor: 5.226

7.  Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa.

Authors:  M P Cranage; A M Whatmore; S A Sharpe; N Cook; N Polyanskaya; S Leech; J D Smith; E W Rud; M J Dennis; G A Hall
Journal:  Virology       Date:  1997-03-03       Impact factor: 3.616

8.  Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome.

Authors:  Lachlan Gray; Jasminka Sterjovski; Melissa Churchill; Philip Ellery; Najla Nasr; Sharon R Lewin; Suzanne M Crowe; Steven L Wesselingh; Anthony L Cunningham; Paul R Gorry
Journal:  Virology       Date:  2005-07-05       Impact factor: 3.616

9.  Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations.

Authors:  Kim M Wilson; Elizabeth I M Johnson; Hayley A Croom; Kim M Richards; Larissa Doughty; Philip H Cunningham; Bruce E Kemp; Bernard M Branson; Elizabeth M Dax
Journal:  AIDS       Date:  2004-11-19       Impact factor: 4.177

10.  Broad neutralization and complement-mediated lysis of HIV-1 by PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody.

Authors:  Erin E Verity; Lisa A Williams; Da'ed N Haddad; Vernon Choy; Chris O'Loughlin; Catherine Chatfield; Nitin K Saksena; Anthony Cunningham; Frank Gelder; Dale A McPhee
Journal:  AIDS       Date:  2006-02-28       Impact factor: 4.177

View more
  12 in total

1.  Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.

Authors:  Madhumita Mahalanabis; Pushpa Jayaraman; Toshiyuki Miura; Florencia Pereyra; E Michael Chester; Barbra Richardson; Bruce Walker; Nancy L Haigwood
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

2.  Short communication: neutralizing antibodies in HIV-1-infected Brazilian individuals.

Authors:  Dalziza Victalina Almeida; Mariza Gonçalvez Morgado; Fernanda Heloise Côrtes; Monick Lindermeyer Guimarães; Leila Mendonça-Lima; Jose Henrique Pilotto; Beatriz Grinsztejn; Valdiléa Gonçalves Veloso; Vera Bongertz
Journal:  AIDS Res Hum Retroviruses       Date:  2012-12-18       Impact factor: 2.205

3.  IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.

Authors:  Kaustuv Banerjee; P J Klasse; Rogier W Sanders; Florencia Pereyra; Elizabeth Michael; Min Lu; Bruce D Walker; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

4.  Lipid metabolism in patients infected with Nef-deficient HIV-1 strain.

Authors:  Hann Low; Lesley Cheng; Maria-Silvana Di Yacovo; Melissa J Churchill; Peter Meikle; Michael Bukrinsky; Andrew F Hill; Dmitri Sviridov
Journal:  Atherosclerosis       Date:  2015-10-30       Impact factor: 5.162

5.  High viral fitness during acute HIV-1 infection.

Authors:  Alicia Arnott; Darren Jardine; Kim Wilson; Paul R Gorry; Kate Merlin; Patricia Grey; Matthew G Law; Elizabeth M Dax; Anthony D Kelleher; Don E Smith; Dale A McPhee
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

6.  Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41.

Authors:  Rachel P J Lai; Jin Yan; Jonathan Heeney; Myra O McClure; Heinrich Göttlinger; Jeremy Luban; Massimo Pizzato
Journal:  PLoS Pathog       Date:  2011-12-15       Impact factor: 6.823

Review 7.  HIV-1 Nef: at the crossroads.

Authors:  John L Foster; J Victor Garcia
Journal:  Retrovirology       Date:  2008-09-22       Impact factor: 4.602

8.  Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection.

Authors:  Wayne B Dyer; John J Zaunders; Fang Fang Yuan; Bin Wang; Jennifer C Learmont; Andrew F Geczy; Nitin K Saksena; Dale A McPhee; Paul R Gorry; John S Sullivan
Journal:  Retrovirology       Date:  2008-12-11       Impact factor: 4.602

9.  Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo.

Authors:  Paul R Gorry; Dale A McPhee; Erin Verity; Wayne B Dyer; Steven L Wesselingh; Jennifer Learmont; John S Sullivan; Michael Roche; John J Zaunders; Dana Gabuzda; Suzanne M Crowe; John Mills; Sharon R Lewin; Bruce J Brew; Anthony L Cunningham; Melissa J Churchill
Journal:  Retrovirology       Date:  2007-09-23       Impact factor: 4.602

10.  Heavily glycosylated, highly fit SIVMne variants continue to diversify and undergo selection after transmission to a new host and they elicit early antibody dependent cellular responses but delayed neutralizing antibody responses.

Authors:  Dawnnica Eastman; Anne Piantadosi; Xueling Wu; Donald N Forthal; Gary Landucci; Jason T Kimata; Julie Overbaugh
Journal:  Virol J       Date:  2008-08-04       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.